BioSpace News Archive

Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced new preclinical data demonstrating in-vitro and in-vivo target engagement and protein upregulation in OPA1 protein-deficient cells.

Dyno Therapeutics, a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced two presentations and a poster at the American Society of Gene and Cell Therapy (ASGCT) conference being held as a virtual meeting on May 12-15, 2020. Details for the presentations and poster are as follows: Presentations Title: Artificial intelli

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) (“China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China , today announced that the Company plans to release its first quarter 2020 financial results on Wednesday, May 20, 2020 after the market closes. The Company’s manage

Amitech Solutions, a leading healthcare data, analytics and automation consulting firm, announces the launch of a new suite of robotic process automation solutions for healthcare.

- Alinity m is Abbott’s new molecular lab system, which was approved by the U.S. FDA in March - The Alinity m system is highly advanced and greatly improves speed and efficiency, running up to 1,080 tests in 24 hours - Abbott is launching Alinity m to U.S. customers and will be making the SARS-CoV-2 test available for use under an Emergency Use Authorization - This is Abbott’s fifth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U

Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced the filing of a new patent application with lead inventor Dr. James Veltmeyer, Chief Medical Officer of TSOI and previously chosen as Top Doctor of San Diego in 2012, 2014, 2016, 2017, and 2019.

Stellar Health, a rapidly growing value-based healthcare technology company headquartered in New York City, announced today that it has raised over $10 million in Series A funding.

Otonomy, Inc. announced preclinical results from the company’s gene therapy collaboration with Applied Genetic Technologies Corporation that support the selection of a product candidate for development as a treatment for gap junction beta-2 deficiency, the most common cause of congenital hearing loss.

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announced positive results from a consumer product test evaluating the efficacy of its shampoo on dermatitis and dandruff. Kane Biotech’s shampoo was developed based on research indicating that the persistence of microbial biofilm may be linked with aggravating the symptoms associated with atopic dermatitis, seborrheic dermatitis (also known as eczema) and dandruff. The

COVID-19 patients from over 10 leading government and private hospitals in India are being enrolled for the study